Venture
Neurelis, Inc.
Latest Form D 2021-03-08- CIK 1481632
- State CA
- Biotechnology
- 8 Form D offerings since 2010-02-03
- Total sold
- $222M
- across 8 offerings
- Rounds
- 8
- Form D offerings since 2010-02-03
- Latest round
- $115M
- 2021-03-08 · 021-391462
- Investors
- 9
- on the latest round
Connected
named in its Form D filingsRound timeline
amount sold · by first filed2021-03-08 · $115M
- 2010-02-03$1.7M021-138380
- 2011-09-30$1.1M021-166626
- 2015-07-16$1.5M021-243911
- 2017-01-06$15M021-277803
- 2018-08-24$5.2M021-320006
- 2018-11-20$40.5M021-326282
- 2020-02-03$42.1M021-359627
- 2021-03-08$115M021-391462
Hover a dot or row, or tab through the dots · bars scaled to the largest round ($115M)
Form D offerings
One line per offering, amendments folded in, newest first
| File | First filed | Latest | Sought | Sold | Investors | Exemptions |
|---|---|---|---|---|---|---|
| 021-391462 | First filed2021-03-08 | Latest2021-03-08 | Sought$120M | Sold$115M | Investors9 | Exemptions506(b) |
| 021-359627 | First filed2020-02-03 | Latest2020-10-16 | Sought$42.1M | Sold$42.1M | Investors26 | Exemptions506(b) |
| 021-326282 | First filed2018-11-20 | Latest2018-11-20 | Sought$40.5M | Sold$40.5M | Investors15 | Exemptions506(b) |
| 021-320006 | First filed2018-08-24 | Latest2018-08-24 | Sought$15M | Sold$5.2M | Investors11 | Exemptions506(b) |
| 021-277803 | First filed2017-01-06 | Latest2017-12-07 | Sought$20M | Sold$15M | Investors2 | Exemptions506(b) |
| 021-243911 | First filed2015-07-16 | Latest2015-07-16 | Sought$10M | Sold$1.5M | Investors1 | Exemptions506(b) |
| 021-166626 | First filed2011-09-30 | Latest2011-09-30 | Sought$1.1M | Sold$1.1M | Investors14 | Exemptions506 |
| 021-138380 | First filed2010-02-03 | Latest2010-02-03 | Sought$2.4M | Sold$1.7M | Investors18 | Exemptions506 |
Who backs Neurelis, Inc., inferred from co-filings, and every Form D as filedSee plans
People
Named in Item 3 of its latest Form D, filed 2021-03-08
| Name | Relationship |
|---|---|
| Craig C. Chambliss | RelationshipExecutive Officer, Director |
| Huaizheng Peng | RelationshipDirector |
| Kevin Li | RelationshipDirector |
| David F. Hale | RelationshipDirector |
| Priyanka Belawat | RelationshipDirector |
| George Stuart | RelationshipExecutive Officer |
| Stephen Cartt | RelationshipDirector |
Sales compensation
Named in Item 12 of its Form D filings
| Recipient | CRD | Broker-dealer | Offerings |
|---|---|---|---|
| Aquilo Partners, L.P. | CRD114909 | Broker-dealer— | Offerings1 |
Facts
As its latest Form D states them
- Industry
- Biotechnology
- State
- California (CA)
- Exemptions
- Rule 506(b); Rule 506
- First filed
- 2010-02-03
- Latest filing
- 2021-03-08
Who backs Neurelis, Inc.
Form D names a startup's officers and directors, not its investors. The dashboard infers them — the venture funds whose own filings and people overlap this company's rounds — and lays every Form D and amendment it filed beside the totals above.
- Inferred investors — the funds and firms behind it, from co-filings and shared people
- Every Form D and amendment as filed, with what each one stated
- Its rounds in sequence: the gap between them and whether they grew
- Everyone its filings name, linked to their other companies, with its addresses and phone numbers
Part of the Venture plan — $140/mo at launch pricing ($350 list)
See plansExternal link: SEC Filings ↗